Follow the people · Insider
Kush Parmar
Kush Parmar files insider transactions with the SEC as a director of Entrada Therapeutics (TRDA). We hold 5 disclosed purchases and sales filed since 25 August 2016, 5 of them in the last 90 days.
- Files forTRDA
- Disclosed buys and sells5 in all, 5 in the last 90 days
- Last disclosure10 August 2026
Positions held
13 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 2 November 2021 — 10 August 2026Director · Entrada Therapeutics (TRDA)30 Form 4 lines · source: SEC Form 4
- Filed 28 July 2021 — 15 May 2024Director · Rallybio (RLYB)21 Form 4 lines · source: SEC Form 4
- Filed 13 March 2024 — 13 March 202410% owner · Skye Bioscience (SKYE)1 Form 4 line · source: SEC Form 4
- Filed 30 June 2020 — 1 December 2022Director and 10% owner · Akouos (AKUS)16 Form 4 lines · source: SEC Form 4
- Filed 27 March 2018 — 15 June 2022Director · Homology Medicines (FIXX)23 Form 4 lines · source: SEC Form 4
- Filed 5 February 2021 — 14 June 2022Director and 10% owner · Vor Biopharma (VOR)12 Form 4 lines · source: SEC Form 4
- Filed 11 January 2022 — 11 January 202210% owner · CinCor Pharma (CINC)7 Form 4 lines · source: SEC Form 4
- Filed 28 October 2021 — 28 October 2021Director and 10% owner · Entrada Therapeutics ((TRDA)1 Form 4 line · source: SEC Form 4
- Filed 27 April 2021 — 27 April 202110% owner · Impel Neuropharma (IMPL)11 Form 4 lines · source: SEC Form 4
- Filed 16 October 2020 — 30 November 2020Co-CEO · 5:01 Acquisition (FVAM)5 Form 4 lines · source: SEC Form 4
- Filed 23 May 2019 — 24 September 2019Director · Arvinas (ARVN)3 Form 4 lines · source: SEC Form 4
- Filed 19 June 2018 — 19 June 2018Director · scPharmaceuticals (SCPH)1 Form 4 line · source: SEC Form 4
- Filed 24 August 2016 — 8 June 2018Director · Audentes Therapeutics (BOLD)3 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 10,494 shares of Entrada TherapeuticsSEC Form 410 August 2026Common Stock · traded 6 August 2026 · filed 10 August 2026
- ▼ sold on the open market 52,317 shares of Entrada TherapeuticsSEC Form 410 August 2026Common Stock · traded 7 August 2026 · filed 10 August 2026
- ▼ sold on the open market 92,444 shares of Entrada TherapeuticsSEC Form 410 August 2026Common Stock · traded 10 August 2026 · filed 10 August 2026
- ▼ sold on the open market 114,756 shares of Entrada TherapeuticsSEC Form 43 August 2026Common Stock · traded 30 July 2026 · filed 3 August 2026
- ▼ sold on the open market 1,718 shares of Entrada TherapeuticsSEC Form 43 August 2026Common Stock · traded 31 July 2026 · filed 3 August 2026
- was granted 19,000 shares of Entrada Therapeutics (a derivative holding)SEC Form 412 June 2026Stock Option (Right to Buy) · traded 10 June 2026 · filed 12 June 2026
- ▼ sold on the open market 200,000 shares of Entrada TherapeuticsSEC Form 418 November 2025Common Stock · traded 14 November 2025 · filed 18 November 2025
- ▼ sold on the open market 20,065 shares of Entrada TherapeuticsSEC Form 411 July 2025Common Stock · traded 9 July 2025 · filed 11 July 2025
- ▼ sold on the open market 6,935 shares of Entrada TherapeuticsSEC Form 411 July 2025Common Stock · traded 9 July 2025 · filed 11 July 2025
- ▼ sold on the open market 55,735 shares of Entrada TherapeuticsSEC Form 41 July 2025Common Stock · traded 27 June 2025 · filed 1 July 2025
- ▼ sold on the open market 19,265 shares of Entrada TherapeuticsSEC Form 41 July 2025Common Stock · traded 27 June 2025 · filed 1 July 2025
- ▼ sold on the open market 18,578 shares of Entrada TherapeuticsSEC Form 41 July 2025Common Stock · traded 30 June 2025 · filed 1 July 2025
- ▼ sold on the open market 6,422 shares of Entrada TherapeuticsSEC Form 41 July 2025Common Stock · traded 30 June 2025 · filed 1 July 2025
- ▼ sold on the open market 18,578 shares of Entrada TherapeuticsSEC Form 41 July 2025Common Stock · traded 1 July 2025 · filed 1 July 2025
- ▼ sold on the open market 6,422 shares of Entrada TherapeuticsSEC Form 41 July 2025Common Stock · traded 1 July 2025 · filed 1 July 2025
- was granted 19,000 shares of Entrada Therapeutics (a derivative holding)SEC Form 412 June 2025Stock Option (Right to Buy) · traded 11 June 2025 · filed 12 June 2025
- was granted 16,000 shares of Entrada Therapeutics (a derivative holding)SEC Form 414 June 2024Stock Option (Right to Buy) · traded 13 June 2024 · filed 14 June 2024
- was granted 16,500 shares of Rallybio (a derivative holding)SEC Form 417 May 2024Option (Right to Buy) · traded 15 May 2024 · filed 17 May 2024
- ▲ bought on the open market 450,000 shares of Skye BioscienceSEC Form 415 March 2024Common Stock · traded 13 March 2024 · filed 15 March 2024
- was granted 27,118 shares of Rallybio (a derivative holding)SEC Form 44 January 2024Option (Right to Buy) · traded 2 January 2024 · filed 4 January 2024
- was granted 16,000 shares of Entrada Therapeutics (a derivative holding)SEC Form 412 June 2023Stock Option (Right to Buy) · traded 8 June 2023 · filed 12 June 2023
- was granted 15,490 shares of Rallybio (a derivative holding)SEC Form 419 May 2023Option (Right to Buy) · traded 17 May 2023 · filed 19 May 2023
- ▼ sold on the open market 100,000 shares of RallybioSEC Form 49 March 2023Common Stock · traded 7 March 2023 · filed 9 March 2023
- was granted 10,344 shares of Rallybio (a derivative holding)SEC Form 45 January 2023Option (Right to Buy) · traded 3 January 2023 · filed 5 January 2023
- returned to the issuer 16,000 shares of Akouos (a derivative holding)SEC Form 42 December 2022Stock Option (right to buy) · traded 1 December 2022 · filed 2 December 2022
- disposed of in a tender offer 3,153,333 shares of AkouosSEC Form 42 December 2022Common Stock · traded 30 November 2022 · filed 2 December 2022
- disposed of in a tender offer 982,453 shares of AkouosSEC Form 42 December 2022Common Stock · traded 30 November 2022 · filed 2 December 2022
- was granted 16,000 shares of Akouos (a derivative holding)SEC Form 427 June 2022Stock Option (right to buy) · traded 23 June 2022 · filed 27 June 2022
- was granted 18,000 shares of Homology Medicines (a derivative holding)SEC Form 417 June 2022Option (Right to Buy) · traded 15 June 2022 · filed 17 June 2022
- was granted 16,911 shares of Vor Biopharma (a derivative holding)SEC Form 416 June 2022Stock Option (right to buy) · traded 14 June 2022 · filed 16 June 2022
- ▼ sold on the open market 99,671 shares of RallybioSEC Form 47 June 2022Common Stock · traded 3 June 2022 · filed 7 June 2022
- ▼ sold on the open market 50,329 shares of RallybioSEC Form 47 June 2022Common Stock · traded 3 June 2022 · filed 7 June 2022
- was granted 11,918 shares of Entrada Therapeutics (a derivative holding)SEC Form 46 June 2022Stock Option (Right to Buy) · traded 2 June 2022 · filed 6 June 2022
- was granted 13,440 shares of Rallybio (a derivative holding)SEC Form 426 May 2022Option (Right to Buy) · traded 24 May 2022 · filed 26 May 2022
- ▼ sold on the open market 66,447 shares of RallybioSEC Form 425 May 2022Common Stock · traded 23 May 2022 · filed 25 May 2022
- ▼ sold on the open market 33,553 shares of RallybioSEC Form 425 May 2022Common Stock · traded 23 May 2022 · filed 25 May 2022
- ▼ sold on the open market 139,539 shares of RallybioSEC Form 410 February 2022Common Stock · traded 8 February 2022 · filed 10 February 2022
- ▼ sold on the open market 70,461 shares of RallybioSEC Form 410 February 2022Common Stock · traded 8 February 2022 · filed 10 February 2022
- converted 9,999,999 shares of CinCor Pharma (a derivative holding)SEC Form 413 January 2022Series A Preferred Stock · traded 11 January 2022 · filed 13 January 2022
- converted 2,525,000 shares of CinCor Pharma (a derivative holding)SEC Form 413 January 2022Series B Preferred Stock · traded 11 January 2022 · filed 13 January 2022
- converted 625,000 shares of CinCor Pharma (a derivative holding)SEC Form 413 January 2022Series B Preferred Stock · traded 11 January 2022 · filed 13 January 2022
- converted 3,683,823 shares of CinCor PharmaSEC Form 413 January 2022Common Stock · traded 11 January 2022 · filed 13 January 2022
- converted 183,823 shares of CinCor PharmaSEC Form 413 January 2022Common Stock · traded 11 January 2022 · filed 13 January 2022
- ▲ bought on the open market 157,500 shares of CinCor PharmaSEC Form 413 January 2022Common Stock · traded 11 January 2022 · filed 13 January 2022
- ▲ bought on the open market 312,500 shares of CinCor PharmaSEC Form 413 January 2022Common Stock · traded 11 January 2022 · filed 13 January 2022
- was granted 5,772 shares of Rallybio (a derivative holding)SEC Form 45 January 2022Option (Right to Buy) · traded 3 January 2022 · filed 5 January 2022
- ▼ sold on the open market 238,870 shares of Vor BiopharmaSEC Form 418 November 2021Common Stock · traded 16 November 2021 · filed 18 November 2021
- ▼ sold on the open market 91,836 shares of Vor BiopharmaSEC Form 418 November 2021Common Stock · traded 16 November 2021 · filed 18 November 2021
- converted 318,616 shares of Entrada Therapeutics (a derivative holding)SEC Form 45 November 2021Series Seed Preferred Stock · traded 2 November 2021 · filed 5 November 2021
- converted 2,371,739 shares of Entrada Therapeutics (a derivative holding)SEC Form 45 November 2021Series A Preferred Stock · traded 2 November 2021 · filed 5 November 2021
- converted 564,217 shares of Entrada Therapeutics (a derivative holding)SEC Form 45 November 2021Series A Preferred Stock · traded 2 November 2021 · filed 5 November 2021
- converted 254,512 shares of Entrada Therapeutics (a derivative holding)SEC Form 45 November 2021Series B Preferred Stock · traded 2 November 2021 · filed 5 November 2021
- converted 318,140 shares of Entrada Therapeutics (a derivative holding)SEC Form 45 November 2021Series B Preferred Stock · traded 2 November 2021 · filed 5 November 2021
- converted 318,616 shares of Entrada TherapeuticsSEC Form 45 November 2021Common Stock · traded 2 November 2021 · filed 5 November 2021
- converted 2,371,739 shares of Entrada TherapeuticsSEC Form 45 November 2021Common Stock · traded 2 November 2021 · filed 5 November 2021
- converted 564,217 shares of Entrada TherapeuticsSEC Form 45 November 2021Common Stock · traded 2 November 2021 · filed 5 November 2021
- converted 254,512 shares of Entrada TherapeuticsSEC Form 45 November 2021Common Stock · traded 2 November 2021 · filed 5 November 2021
- converted 318,140 shares of Entrada TherapeuticsSEC Form 45 November 2021Common Stock · traded 2 November 2021 · filed 5 November 2021
- ▲ bought on the open market 250,000 shares of Entrada TherapeuticsSEC Form 45 November 2021Common Stock · traded 2 November 2021 · filed 5 November 2021
- was granted 23,552 shares of Entrada Therapeutics (a derivative holding)SEC Form 41 November 2021Stock Option (Right to Buy) · traded 28 October 2021 · filed 1 November 2021
- acquired or disposed of, other 1,795,946 shares of Rallybio (a derivative holding)SEC Form 44 August 2021Series A-1 Preferred Units · traded 28 July 2021 · filed 4 August 2021
- acquired or disposed of, other 8,742,654 shares of Rallybio (a derivative holding)SEC Form 44 August 2021Series A-2 Preferred Units · traded 28 July 2021 · filed 4 August 2021
- acquired or disposed of, other 7,192,795 shares of Rallybio (a derivative holding)SEC Form 44 August 2021Series B Preferred Units · traded 28 July 2021 · filed 4 August 2021
- acquired or disposed of, other 5,034,955 shares of Rallybio (a derivative holding)SEC Form 44 August 2021Series B Preferred Units · traded 28 July 2021 · filed 4 August 2021
- was granted 13,440 shares of Rallybio (a derivative holding)SEC Form 44 August 2021Option (Right to Buy) · traded 28 July 2021 · filed 4 August 2021
- acquired or disposed of, other 2,784,626 shares of RallybioSEC Form 44 August 2021Common Stock · traded 28 July 2021 · filed 4 August 2021
- acquired or disposed of, other 790,714 shares of RallybioSEC Form 44 August 2021Common Stock · traded 28 July 2021 · filed 4 August 2021
- ▲ bought on the open market 615,384 shares of RallybioSEC Form 44 August 2021Common Stock · traded 2 August 2021 · filed 4 August 2021
- was granted 16,000 shares of Akouos (a derivative holding)SEC Form 425 June 2021Stock Option (right to buy) · traded 24 June 2021 · filed 25 June 2021
- was granted 18,000 shares of Homology Medicines (a derivative holding)SEC Form 422 June 2021Option (Right to Buy) · traded 17 June 2021 · filed 22 June 2021
- converted 13,233,885 shares of Impel Neuropharma (a derivative holding)SEC Form 429 April 2021Series C-1 Preferred Stock · traded 27 April 2021 · filed 29 April 2021
- converted 8,845,942 shares of Impel Neuropharma (a derivative holding)SEC Form 429 April 2021Series C-2 Preferred Stock · traded 27 April 2021 · filed 29 April 2021
- converted 8,201,930 shares of Impel Neuropharma (a derivative holding)SEC Form 429 April 2021Series C-3 Preferred Stock · traded 27 April 2021 · filed 29 April 2021
- converted 5,876,034 shares of Impel Neuropharma (a derivative holding)SEC Form 429 April 2021Series D Preferred Stock · traded 27 April 2021 · filed 29 April 2021
- converted 1,359,799 shares of Impel Neuropharma (a derivative holding)SEC Form 429 April 20215% Convertible Note due 2021 · traded 27 April 2021 · filed 29 April 2021
- converted 808,259 shares of Impel NeuropharmaSEC Form 429 April 2021Common Stock · traded 27 April 2021 · filed 29 April 2021
- converted 540,265 shares of Impel NeuropharmaSEC Form 429 April 2021Common Stock · traded 27 April 2021 · filed 29 April 2021
- converted 500,932 shares of Impel NeuropharmaSEC Form 429 April 2021Common Stock · traded 27 April 2021 · filed 29 April 2021
- converted 358,878 shares of Impel NeuropharmaSEC Form 429 April 2021Common Stock · traded 27 April 2021 · filed 29 April 2021
- converted 101,457 shares of Impel NeuropharmaSEC Form 429 April 2021Common Stock · traded 27 April 2021 · filed 29 April 2021
- ▲ bought on the open market 575,000 shares of Impel NeuropharmaSEC Form 429 April 2021Common Stock · traded 27 April 2021 · filed 29 April 2021
- was granted 16,900 shares of Vor Biopharma (a derivative holding)SEC Form 49 February 2021Stock Option (right to buy) · traded 5 February 2021 · filed 9 February 2021
- converted 45,000,000 shares of Vor Biopharma (a derivative holding)SEC Form 49 February 2021Series A-2 Preferred Stock · traded 9 February 2021 · filed 9 February 2021
- converted 19,230,768 shares of Vor Biopharma (a derivative holding)SEC Form 49 February 2021Series B Preferred Stock · traded 9 February 2021 · filed 9 February 2021
- converted 19,230,768 shares of Vor Biopharma (a derivative holding)SEC Form 49 February 2021Series B Preferred Stock · traded 9 February 2021 · filed 9 February 2021
- converted 3,308,822 shares of Vor BiopharmaSEC Form 49 February 2021Common Stock · traded 9 February 2021 · filed 9 February 2021
- converted 1,414,026 shares of Vor BiopharmaSEC Form 49 February 2021Common Stock · traded 9 February 2021 · filed 9 February 2021
- ▲ bought on the open market 111,111 shares of Vor BiopharmaSEC Form 49 February 2021Common Stock · traded 9 February 2021 · filed 9 February 2021
- converted 1,414,026 shares of Vor BiopharmaSEC Form 49 February 2021Common Stock · traded 9 February 2021 · filed 9 February 2021
- ▲ bought on the open market 444,444 shares of Vor BiopharmaSEC Form 49 February 2021Common Stock · traded 9 February 2021 · filed 9 February 2021
- ▼ sold on the open market 358,352 shares of AkouosSEC Form 431 December 2020Common Stock · traded 29 December 2020 · filed 31 December 2020
- ▼ sold on the open market 111,648 shares of AkouosSEC Form 431 December 2020Common Stock · traded 29 December 2020 · filed 31 December 2020
- ▼ sold on the open market 480,000 shares of Homology MedicinesSEC Form 428 December 2020Common Stock · traded 22 December 2020 · filed 28 December 2020
- ▼ sold on the open market 20,000 shares of Homology MedicinesSEC Form 428 December 2020Common Stock · traded 22 December 2020 · filed 28 December 2020
- ▼ sold on the open market 151,138 shares of Homology MedicinesSEC Form 416 December 2020Common Stock · traded 14 December 2020 · filed 16 December 2020
- ▼ sold on the open market 328,862 shares of Homology MedicinesSEC Form 416 December 2020Common Stock · traded 14 December 2020 · filed 16 December 2020
- ▼ sold on the open market 6,297 shares of Homology MedicinesSEC Form 416 December 2020Common Stock · traded 14 December 2020 · filed 16 December 2020
- ▼ sold on the open market 13,703 shares of Homology MedicinesSEC Form 416 December 2020Common Stock · traded 14 December 2020 · filed 16 December 2020
- acquired or disposed of, other 235,932 shares of 5:01 Acquisition (a derivative holding)SEC Form 41 December 2020Class B Common Stock · traded 30 November 2020 · filed 1 December 2020
- acquired or disposed of, other 30,000 shares of 5:01 Acquisition (a derivative holding)SEC Form 418 November 2020Class B Common Stock · traded 17 November 2020 · filed 18 November 2020
- acquired or disposed of, other 5,126 shares of 5:01 AcquisitionSEC Form 412 November 2020Class A Common Stock · traded 12 November 2020 · filed 12 November 2020
- acquired or disposed of, other 90,000 shares of 5:01 Acquisition (a derivative holding)SEC Form 420 October 2020Class B Common Stock · traded 16 October 2020 · filed 20 October 2020
- acquired or disposed of, other 360,000 shares of 5:01 AcquisitionSEC Form 420 October 2020Class A Common Stock · traded 16 October 2020 · filed 20 October 2020
- converted 10,826,417 shares of Akouos (a derivative holding)SEC Form 42 July 2020Series Seed Preferred Stock · traded 30 June 2020 · filed 2 July 2020
- converted 42,102,730 shares of Akouos (a derivative holding)SEC Form 42 July 2020Series A Preferred Stock · traded 30 June 2020 · filed 2 July 2020
- converted 21,072,595 shares of Akouos (a derivative holding)SEC Form 42 July 2020Series B Preferred Stock · traded 30 June 2020 · filed 2 July 2020
- converted 16,858,076 shares of Akouos (a derivative holding)SEC Form 42 July 2020Series B Preferred Stock · traded 30 June 2020 · filed 2 July 2020
- converted 513,757 shares of AkouosSEC Form 42 July 2020Common Stock · traded 30 June 2020 · filed 2 July 2020
- converted 1,997,946 shares of AkouosSEC Form 42 July 2020Common Stock · traded 30 June 2020 · filed 2 July 2020
- converted 999,980 shares of AkouosSEC Form 42 July 2020Common Stock · traded 30 June 2020 · filed 2 July 2020
- converted 799,984 shares of AkouosSEC Form 42 July 2020Common Stock · traded 30 June 2020 · filed 2 July 2020
- ▲ bought on the open market 294,117 shares of AkouosSEC Form 42 July 2020Common Stock · traded 30 June 2020 · filed 2 July 2020
- was granted 18,000 shares of Homology Medicines (a derivative holding)SEC Form 412 June 2020Option (Right to Buy) · traded 10 June 2020 · filed 12 June 2020
- gave away 1,700 shares of ArvinasSEC Form 426 September 2019Common Stock · traded 24 September 2019 · filed 26 September 2019
- acquired or disposed of, other 3,475 shares of ArvinasSEC Form 418 September 2019Common Stock · traded 16 September 2019 · filed 18 September 2019
- was granted 15,580 shares of Homology Medicines (a derivative holding)SEC Form 410 June 2019Option (Right to Buy) · traded 6 June 2019 · filed 10 June 2019
- was granted 12,923 shares of Arvinas (a derivative holding)SEC Form 428 May 2019Stock Option (right to buy) · traded 23 May 2019 · filed 28 May 2019
- ▼ sold on the open market 590,400 shares of Homology MedicinesSEC Form 420 May 2019Common Stock · traded 16 May 2019 · filed 20 May 2019
- ▼ sold on the open market 24,600 shares of Homology MedicinesSEC Form 420 May 2019Common Stock · traded 16 May 2019 · filed 20 May 2019
- ▼ sold on the open market 14,952 shares of Homology MedicinesSEC Form 412 December 2018Common Stock · traded 10 December 2018 · filed 12 December 2018
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.